Sudden Cardiac Death News and Research

RSS

The term sudden cardiac death refers to natural death from cardiac causes, heralded by abrupt loss of consciousness within one hour of the onset of acute symptoms.

Gene sequencer donated for cardiovascular research

The Foundation has donated a latest-generation gene sequencer to the hospital's Cardiovascular Research Unit for use in its research project "Genetic testing in cardiovascular pathologies linked to sudden cardiac death among young athletes".

9 Oct 2009

Therapeutic hypothermia after CPR improves survival and lessens brain damage

Cooling a person's body within six hours of cardiac arrest with successful CPR might improve survival and lessen brain damage, according to a new Cochrane review.

9 Oct 2009

Findings from a study of Vicor's PD2i VS to be presented at the Resuscitation Science Symposium 2009

David H. Fater, CEO of Vicor Technologies, Inc., today announced that Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), will present findings from a study of Vicor's PD2i VS™ (Vital Sign) at the American Heart Association's Resuscitation Science Symposium 2009 on November 14-15, 2009 in Orlando, Florida.

7 Oct 2009

Hypertrophic Cardiomyopathy causes sudden cardiac death in children and young adults

Since Congress declared October “National Sudden Cardiac Arrest Awareness Month” one year ago, more than 250,000 Americans have suffered SCA. For too many, the underlying cause was Hypertrophic Cardiomyopathy (HCM), an inherited disease that affects one out of 500 Americans. What makes it all the more troubling is that early diagnosis of HCM through simple and inexpensive screening can reduce the risk of sudden cardiac death.

6 Oct 2009

Increase in omega-3 fatty acid levels can prevent strokes, according to research

Research led by Hernan A. Bazan, MD, Assistant Professor of Surgery, Section of Vascular Surgery, at LSU Health Sciences Center New Orleans School of Medicine, has found that unstable carotid artery plaques - those in danger of rupturing and leading to a stroke - contain more inflammation and significantly less omega-3 fatty acids than asymptomatic plaques.

3 Oct 2009

Altered state physiology drug development platform to treat an array of human conditions

David H. Fater, CEO of Vicor Technologies, Inc., today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

1 Oct 2009

NIH grants $5 million to Pittsburgh researchers

Regenerative medicine researchers at the University of Pittsburgh received two grants totaling more than $5 million from the National Institutes of Health (NIH) to explore new methods for cultivating replacement cells from existing tissues and organs.

26 Sep 2009

PROSPECT clinical trial results announced

Abbott today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial.

25 Sep 2009

Vicor's PD2i heart-rate complexity metric to be tested on trauma patients in U.S. Army's C3E program

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Colonel Leopoldo Cancio of the U.S. Army Institute of Surgical Research (USAISR) identified its PD2i as a heart rate complexity metric that will be tested on trauma patients under the new Critical Combat Care Engineering (C3E) program.

23 Sep 2009

Study reveals that KCNE2 and KCNQ1 mutations can results in thyroid dysfunction

Genes previously known to be essential to the coordinated, rhythmic electrical activity of cardiac muscle -- a healthy heartbeat -- have now also been found to play a key role in thyroid hormone (TH) biosynthesis, according to Weill Cornell Medical College researchers.

21 Sep 2009

Lantheus commences Phase 1 study evaluating novel LMI1195 heart failure imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.

17 Sep 2009

Implantable defibrillator therapy not beneficial for women with heart failure

Implantable cardioverter-defibrillators do not appear to be associated with a reduced risk of death in women with advanced heart failure, according to a meta-analysis of previously published research in the September 14 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Sep 2009

Pfizer pleads guilty of defrauding Medicare, Medicaid and other government-funded health care programs

Pfizer, Inc. announced today it has agreed to plead guilty to criminal conduct and to pay more than $2 billion in criminal and civil fines, penalties and damages to settle allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for four of its drugs. The settlement is the largest qui tam settlement in U.S. history.

3 Sep 2009

CRT-D implants for treating sudden cardiac death

Electrophysiologists Robert Stevenson, MD, and Jeffrey L. Williams, MD, MS, FACC, are safely implanting cardiac resynchronization therapy defibrillators in the Good Samaritan Hospital (GSH) Cardiology (Heart Failure) Program.

3 Sep 2009

ICD implantation reduces mortality in heart attack patients

Findings from the latest PreSCD II analysis show that patients protected against sudden cardiac death by an implantable cardioverter defibrillator (ICD) one month or more after MI showed a non-significantRemarkably," says investigator Professor Heinz Völler from the Klinik am See in Ruedersdorf, Germany, "we observed in the data a survival benefit that increased with the time interval between MI and ICD implantation."

2 Sep 2009

Defibrillator-cardiac resynchronization therapy combination reduces heat failure risk

Patients who had a cardiac resynchronization device combined with a defibrillator (CRT-D) implanted had a 34 percent reduction in their risk of death or heart failure when compared to patients receiving only an implanted cardiac defibrillator (ICD), according to a landmark study published online today in the New England Journal of Medicine and presented today at the European Society of Cardiology Congress (ESC) in Barcelona, Spain.

2 Sep 2009

Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress

Boston Scientific Corporation today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial.

28 Aug 2009

NYP/Weill Cornell research reveals that prolonged QRS duration indicates abnormal pumping of the heart

QRS duration (QRSd) is one of several measures of heart function recorded during a routine electrocardiogram (ECG). It is a composite of waves showing the length of time it takes for an electrical signal to get all the way through the pumping chambers of the heart. Prolonged QRSd is a sign of an abnormal electrical system of the heart and is often found when the heart isn't pumping efficiently.

28 Aug 2009

Cardiac Science Corporation installs 195 Powerheart AED G3 devices in Atlanta Public School

Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, announced the expansion of the largest AED deployment of any school system in Georgia with 195 Powerheart AED G3 devices from Cardiac Science.

26 Aug 2009

PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

David H. Fater, CEO of Vicor Technologies, Inc., today announced that original research conducted using its PD2i algorithm to prospectively predict risk of sudden cardiac death was published in Therapeutics and Clinical Risk Management.